The company is asking for customers to identify and destroy 51 human and 33 animal drug products, according to an April 26 post from the FDA. Some of the recalled human drugs include albuterol, lorazepam and naloxone.
“The discontinuation of the quality program means the company will not be able to support or guarantee that the products will meet all intended specifications through the labeled shelf life of the product,” the FDA said. “Further distribution or use of any remaining product on the market should cease immediately.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.